STOCK TITAN

[8-K] Weyerhaeuser Company Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) – Form 144 filing discloses a planned sale of 41,801 common shares through Fidelity Brokerage Services on or about 07/24/2025. The shares carry an aggregate market value of US$18.94 million, implying an estimated price of roughly US$453 per share. With 28.09 million shares outstanding, the proposed disposition equals approximately 0.15 % of total shares, a relatively small portion of the float.

No other MEDP securities were sold by the same account during the past three months, and the filer certifies the absence of undisclosed adverse information. The document does not reveal the seller’s name, relationship to the company, or whether the trade is under a Rule 10b5-1 plan, leaving limited insight into the motivation behind the sale.

Medpace Holdings, Inc. (MEDP) – Comunicazione Form 144 annuncia una vendita pianificata di 41.801 azioni ordinarie tramite Fidelity Brokerage Services intorno al 24/07/2025. Le azioni hanno un valore di mercato complessivo di 18,94 milioni di dollari USA, corrispondente a un prezzo stimato di circa 453 dollari per azione. Con 28,09 milioni di azioni in circolazione, la vendita proposta rappresenta circa lo 0,15% del totale delle azioni, una quota relativamente piccola del flottante.

Negli ultimi tre mesi non sono state vendute altre azioni MEDP dallo stesso conto, e il dichiarante certifica l'assenza di informazioni negative non divulgate. Il documento non rivela il nome del venditore, il suo rapporto con la società, né se la transazione avviene nell'ambito di un piano Rule 10b5-1, lasciando quindi limitate informazioni sulle motivazioni della vendita.

Medpace Holdings, Inc. (MEDP) – Presentación del Formulario 144 revela una venta planificada de 41,801 acciones comunes a través de Fidelity Brokerage Services alrededor del 24/07/2025. Las acciones tienen un valor de mercado agregado de 18,94 millones de dólares estadounidenses, lo que implica un precio estimado de aproximadamente 453 dólares por acción. Con 28,09 millones de acciones en circulación, la disposición propuesta equivale aproximadamente al 0,15% del total de acciones, una porción relativamente pequeña del flotante.

No se vendieron otros valores de MEDP desde la misma cuenta en los últimos tres meses, y el declarante certifica la ausencia de información adversa no divulgada. El documento no revela el nombre del vendedor, su relación con la empresa ni si la operación se realiza bajo un plan Rule 10b5-1, dejando limitada información sobre la motivación detrás de la venta.

Medpace Holdings, Inc. (MEDP) – Form 144 제출은 Fidelity Brokerage Services를 통해 41,801주 보통주를 2025년 7월 24일경에 판매할 계획임을 공개합니다. 해당 주식의 총 시장 가치는 1,894만 달러로, 주당 약 453달러로 추산됩니다. 2,809만 주가 발행된 상황에서 이번 매도는 전체 주식의 약 0.15%에 해당하는 비교적 적은 비중입니다.

지난 3개월 동안 동일 계좌에서 다른 MEDP 증권이 매도된 적 없으며, 제출자는 미공개 불리한 정보가 없음을 인증했습니다. 문서에는 매도자의 이름, 회사와의 관계, 또는 Rule 10b5-1 계획에 따른 거래인지 여부가 공개되지 않아 매도 동기에 대한 정보가 제한적입니다.

Medpace Holdings, Inc. (MEDP) – Dépôt du Formulaire 144 révèle une vente prévue de 41 801 actions ordinaires via Fidelity Brokerage Services aux alentours du 24/07/2025. Les actions représentent une valeur marchande totale de 18,94 millions de dollars US, ce qui implique un prix estimé d'environ 453 dollars par action. Avec 28,09 millions d’actions en circulation, cette cession représente environ 0,15 % du total des actions, une part relativement faible du flottant.

Aucun autre titre MEDP n’a été vendu par le même compte au cours des trois derniers mois, et le déclarant certifie l’absence d’informations défavorables non divulguées. Le document ne révèle pas le nom du vendeur, sa relation avec la société, ni si la transaction s’inscrit dans un plan Rule 10b5-1, ce qui limite la compréhension des motivations derrière cette vente.

Medpace Holdings, Inc. (MEDP) – Form 144 Einreichung gibt den geplanten Verkauf von 41.801 Stammaktien über Fidelity Brokerage Services um den 24.07.2025 bekannt. Die Aktien haben einen gesamten Marktwert von 18,94 Millionen US-Dollar, was einem geschätzten Preis von etwa 453 US-Dollar pro Aktie entspricht. Bei 28,09 Millionen ausstehenden Aktien entspricht die geplante Veräußerung etwa 0,15 % der Gesamtaktien, ein vergleichsweise kleiner Anteil am Streubesitz.

In den letzten drei Monaten wurden keine weiteren MEDP-Wertpapiere vom selben Konto verkauft, und der Einreicher bestätigt das Fehlen nicht offengelegter negativer Informationen. Das Dokument nennt weder den Namen des Verkäufers, dessen Beziehung zum Unternehmen, noch ob der Handel im Rahmen eines Rule 10b5-1-Plans erfolgt, was die Einsicht in die Verkaufsgründe einschränkt.

Positive
  • Sale represents only ~0.15 % of outstanding shares, indicating minimal dilution or ownership impact.
  • No other insider sales reported in the prior three months, reducing concerns of a broader disposal trend.
Negative
  • Insider intends to sell US$18.94 million in stock, which can be perceived as a negative sentiment signal.
  • Filing omits the seller’s identity and relationship to MEDP, limiting transparency for investors.

Insights

TL;DR: $18.9 M sale (0.15 % float) is modest; neutral-to-slightly negative signal given missing seller details.

The filing flags an insider-level disposition but the absolute and relative sizes are small, so dilution and control effects are negligible. Absence of past-90-day sales suggests no ongoing liquidation trend. However, lack of disclosure around the seller and any 10b5-1 plan limits transparency, preventing investors from evaluating whether the move is routine diversification or reflects a less favorable outlook. Until identity and context are clarified, the market impact should remain muted, but risk-averse investors may view any insider sale as a cautionary note.

Medpace Holdings, Inc. (MEDP) – Comunicazione Form 144 annuncia una vendita pianificata di 41.801 azioni ordinarie tramite Fidelity Brokerage Services intorno al 24/07/2025. Le azioni hanno un valore di mercato complessivo di 18,94 milioni di dollari USA, corrispondente a un prezzo stimato di circa 453 dollari per azione. Con 28,09 milioni di azioni in circolazione, la vendita proposta rappresenta circa lo 0,15% del totale delle azioni, una quota relativamente piccola del flottante.

Negli ultimi tre mesi non sono state vendute altre azioni MEDP dallo stesso conto, e il dichiarante certifica l'assenza di informazioni negative non divulgate. Il documento non rivela il nome del venditore, il suo rapporto con la società, né se la transazione avviene nell'ambito di un piano Rule 10b5-1, lasciando quindi limitate informazioni sulle motivazioni della vendita.

Medpace Holdings, Inc. (MEDP) – Presentación del Formulario 144 revela una venta planificada de 41,801 acciones comunes a través de Fidelity Brokerage Services alrededor del 24/07/2025. Las acciones tienen un valor de mercado agregado de 18,94 millones de dólares estadounidenses, lo que implica un precio estimado de aproximadamente 453 dólares por acción. Con 28,09 millones de acciones en circulación, la disposición propuesta equivale aproximadamente al 0,15% del total de acciones, una porción relativamente pequeña del flotante.

No se vendieron otros valores de MEDP desde la misma cuenta en los últimos tres meses, y el declarante certifica la ausencia de información adversa no divulgada. El documento no revela el nombre del vendedor, su relación con la empresa ni si la operación se realiza bajo un plan Rule 10b5-1, dejando limitada información sobre la motivación detrás de la venta.

Medpace Holdings, Inc. (MEDP) – Form 144 제출은 Fidelity Brokerage Services를 통해 41,801주 보통주를 2025년 7월 24일경에 판매할 계획임을 공개합니다. 해당 주식의 총 시장 가치는 1,894만 달러로, 주당 약 453달러로 추산됩니다. 2,809만 주가 발행된 상황에서 이번 매도는 전체 주식의 약 0.15%에 해당하는 비교적 적은 비중입니다.

지난 3개월 동안 동일 계좌에서 다른 MEDP 증권이 매도된 적 없으며, 제출자는 미공개 불리한 정보가 없음을 인증했습니다. 문서에는 매도자의 이름, 회사와의 관계, 또는 Rule 10b5-1 계획에 따른 거래인지 여부가 공개되지 않아 매도 동기에 대한 정보가 제한적입니다.

Medpace Holdings, Inc. (MEDP) – Dépôt du Formulaire 144 révèle une vente prévue de 41 801 actions ordinaires via Fidelity Brokerage Services aux alentours du 24/07/2025. Les actions représentent une valeur marchande totale de 18,94 millions de dollars US, ce qui implique un prix estimé d'environ 453 dollars par action. Avec 28,09 millions d’actions en circulation, cette cession représente environ 0,15 % du total des actions, une part relativement faible du flottant.

Aucun autre titre MEDP n’a été vendu par le même compte au cours des trois derniers mois, et le déclarant certifie l’absence d’informations défavorables non divulguées. Le document ne révèle pas le nom du vendeur, sa relation avec la société, ni si la transaction s’inscrit dans un plan Rule 10b5-1, ce qui limite la compréhension des motivations derrière cette vente.

Medpace Holdings, Inc. (MEDP) – Form 144 Einreichung gibt den geplanten Verkauf von 41.801 Stammaktien über Fidelity Brokerage Services um den 24.07.2025 bekannt. Die Aktien haben einen gesamten Marktwert von 18,94 Millionen US-Dollar, was einem geschätzten Preis von etwa 453 US-Dollar pro Aktie entspricht. Bei 28,09 Millionen ausstehenden Aktien entspricht die geplante Veräußerung etwa 0,15 % der Gesamtaktien, ein vergleichsweise kleiner Anteil am Streubesitz.

In den letzten drei Monaten wurden keine weiteren MEDP-Wertpapiere vom selben Konto verkauft, und der Einreicher bestätigt das Fehlen nicht offengelegter negativer Informationen. Das Dokument nennt weder den Namen des Verkäufers, dessen Beziehung zum Unternehmen, noch ob der Handel im Rahmen eines Rule 10b5-1-Plans erfolgt, was die Einsicht in die Verkaufsgründe einschränkt.

0000106535false00001065352025-07-242025-07-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2025

 

 

WEYERHAEUSER COMPANY

(Exact name of registrant as specified in charter)

 

 

Washington

1-4825

91-0470860

 

 

 

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(IRS Employer

Identification Number)

 

220 Occidental Avenue South

Seattle, Washington 98104-7800

(Address of principal executive offices)

(zip code)

Registrant’s telephone number, including area code:

(206) 539-3000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $1.25 per share

 

WY

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

TABLE OF CONTENTS

 

 

Item 2.02. Results of Operations and Financial Condition

 

Item 9.01. Financial Statements and Exhibits

 

SIGNATURES

 

EXHIBIT 99.1

 

EXHIBIT 99.2

 

 


Table of Contents

Section 2 - Financial Information

Item 2.02. Results of Operations and Financial Condition

On July 24, 2025, Weyerhaeuser Company will post and make available on its website its financial results for the quarter ended June 30, 2025. Copies of the earnings release and the exhibit thereto are furnished as Exhibit 99.1 and Exhibit 99.2 to this report.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits. The following items are furnished as exhibits to this report.

 

 

 

 

 

Exhibit No.

Description

 

99.1

Earnings release of Weyerhaeuser Company posted July 24, 2025 reporting results of operations for the quarter ended June 30, 2025.

 

99.2

Exhibit to earnings release of Weyerhaeuser Company posted July 24, 2025.

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

WEYERHAEUSER COMPANY

 

 

By:

 

/s/ Alex G. Whitney

Name:

 

Alex G. Whitney

Its:

 

Vice President and Chief Accounting Officer

 

 

(Principal Accounting Officer)

 

Date: July 24, 2025

 

 


FAQ

How many Medpace (MEDP) shares are being sold under this Form 144?

The filing covers 41,801 common shares of Medpace Holdings, Inc.

What is the dollar value of the proposed MEDP share sale?

The aggregate market value is approximately US$18.94 million.

What percentage of Medpace’s outstanding shares does the sale represent?

It equates to about 0.15 % of the 28.09 million shares outstanding.

When is the anticipated sale date for the MEDP shares?

The approximate sale date listed is 07/24/2025.

Were any MEDP shares sold by this insider in the past three months?

No; the filing states “Nothing to Report” for prior 3-month sales.

Is the trade linked to a Rule 10b5-1 plan?

The Form 144 does not specify whether the sale is under a 10b5-1 trading plan.
Weyerhaeuser

NYSE:WY

WY Rankings

WY Latest News

WY Latest SEC Filings

WY Stock Data

18.83B
722.87M
0.31%
89.45%
1.2%
REIT - Specialty
Real Estate Investment Trusts
Link
United States
SEATTLE